MP80-07 SEX CORD-GONADAL STROMAL TUMORS OF THE TESTICLE ARE FAR MORE LETHAL THAN GERM CELL TESTICULAR NEOPLASMS

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Penis/Testis/Urethra: Benign Disease & Malignant Disease III1 Apr 2017MP80-07 SEX CORD-GONADAL STROMAL TUMORS OF THE TESTICLE ARE FAR MORE LETHAL THAN GERM CELL TESTICULAR NEOPLASMS Joel Slaton, Jet Li, Ngoc Duong, and Kai Ding Joel SlatonJoel Slaton More articles by this author , Jet LiJet Li More articles by this author , Ngoc DuongNgoc Duong More articles by this author , and Kai DingKai Ding More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2512AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Sex cord-gonadal stromal tumors (SCGS) of the testicle, primarily made up of Leydig cell and Sertoli cell tumors, are rare testicular neoplasms. Single institutional studies suggest that metastases are rare and survival excellent. We utilized the SEER database to characterize risks of metastasis in patients with SCGS tumors. METHODS We interrogated the SEER database from 1973 to 2010 to identify all Leydig cell (code -86503) and Sertoli cell (code -86403) tumors among male patients. Data collected and analyzed included patient age and race; SEER stage including limited to primary site (Localized), the presence of disease in retroperitoneal lymph nodes (Regional) and distant metastases (Distant); as well as cancer-specific and overall survival. RESULTS We identified 53 patients with Leydig cell tumors and 23 with Sertoli cell tumors. Sertoli cell tumors were fairly evenly distributed overall all age groups while Leydig cell tumors were concentrated among ages 30-59. Using SEER extent of disease, 79% were found to be Localized and 21% Distant on initial presentation with equal distribution among patients with Leydig and Sertoli cell tumors. Median survival of patients presenting with metastases was 27 months. Patients with apparently Localized disease had a 13% chance of developing metastases at a median of 17 months. Patients with SCGS tumors of the testicle whether localized or metastatic had a significantly poorer survival compared to patients with germ cell tumors. CONCLUSIONS This study represents the largest analysis of outcomes for patients with SCGS tumors. These neoplasms have a high risk of presenting with metastasis (20%) than previously recognized as as well as a significant risk (13%) of patients with Localized tumor developing a recurrence. Patients with metastatic SCGS tumors are at higher risk of dying from their disease than patients with metastatic germ cell neoplasms likely due to inherent resistance to radiation and chemotherapy. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1083 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Joel Slaton More articles by this author Jet Li More articles by this author Ngoc Duong More articles by this author Kai Ding More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...